RT Journal Article
T1 SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)
A1 Vaz-Salgado, Maria Angeles
A1 Cigarral-Garcia, Belen
A1 Fernandez-Perez, Isaura
A1 Jimenez-Munarriz, Beatriz
A1 Sampedro-Domarco, Paula
A1 Hernandez-Gonzalez, Ainhoa
A1 Vieito-Villar, Maria
A1 Luque-Caro, Raquel
A1 Villamayor-Delgado, Maria Luisa
A1 Sepulveda-Sanchez, Juan Manuel
K1 Astrocytoma
K1 Guideline
K1 IDH mutation
K1 Low-grade glioma
K1 Neuro-oncology
K1 Oligodendroglioma
AB The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.
PB Springer
SN 1699-3055
YR 2024
FD 2024-04-25
LK https://hdl.handle.net/10668/28621
UL https://hdl.handle.net/10668/28621
LA en
NO Vaz-Salgado MÁ, García BC, Pérez IF, Munárriz BJ, Domarco PS, González AH, et al. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023). Clin Transl Oncol. 2024 Nov;26(11):2856-2865
DS RISalud
RD Nov 5, 2025